Wilmington Healthcare launches new platform to map the formulary landscape
February 4, 2021 |
Healthcare intelligence provider Wilmington Healthcare has launched a new platform that enables pharma companies to develop a clear picture of formulary status across therapy areas and territories in the UK.
4 February 2021
Wilmington Healthcare launches new platform to map the formulary landscape
Healthcare intelligence provider Wilmington Healthcare has launched a new platform that enables pharma companies to develop a clear picture of formulary status across therapy areas and territories in the UK.
Known as InFormulary XD, the solution uses a unique blend of data and real-world evidence to provide an objective view of the status of a product by indication, on formularies and within guidelines.
Users can drill down into NHS localities within defined territories to gain a more detailed view of how their products are performing in primary and secondary care and better understand the challenges where formularies overlap.
The tool’s grading system also enables companies to clearly see where their brands sit on formularies and benchmark their performance against the competition using a wealth of data and insight.
In addition, the platform can be used to connect formulary information with other data sources, such as key stakeholder databases and NHS documents associated with product indication and target formularies.
Armed with data and insights from the platform, pharma can create compelling go-to-market plans to improve or maintain market position, monitor progress and keep abreast of formulary changes at a glance.
Gareth Thomas, Managing Director of Wilmington Healthcare, said: “The formulary landscape is not only multi-layered and complex, it is also changing quickly as the NHS adopts the integrated care models outlined in the Long-term Plan. This means that formulary data must be regularly reviewed and updated.
“Our new InFormulary XD enables customers to build and maintain a comprehensive view of a product’s formulary status in the UK in real-time and benchmark its performance against the competition. This level of insight, combined with related stakeholder data, gives companies a real competitive advantage in everything from strategic planning, budgeting and resourcing to customer targeting.”
Ends
Notes to Editors
For more information, please contact: Andrew Baud and Catherine McNulty, Tala, +44 (0) 20 3397 3383 or +44 (0) 7775 715775, Email: andrew.baud@teamtala.com /catherine.mcnulty@teamtala.com
This content was provided by Wilmington Healthcare
Company Details
Latest Content from Wilmington Healthcare
Wilmington Healthcare appoints new director to lead cloud-based healthcare customer intelligence tool
Paul Rowe to lead intelligence tool that allows Industry to gain the complete picture of their changing NHS customer base and employ precision planning to access target customers and markets.
LOOKING AHEAD: UNDERSTANDING THE NHS CUSTOMER’S PRIORITIES FOR 2022/23
The recently published operational planning guidance describes what the NHS needs to achieve this year. Wilmington Healthcare’s Oli Hudson explores some of its critical themes and what they mean for...
NAVIGATING 2022: THE FIVE CRITICAL SHIFTS PHARMA NEEDS TO EMBRACE
With a stormy outlook predicted for health and care, Wilmington Healthcare’s Oli Hudson looks at the five critical shifts that pharma should focus on as it navigates its way through...
CHANGING FACES: UNDERSTANDING THE KEY CUSTOMER CONTACT POINTS WITHIN THE ICS LANDSCAPE
As well as creating new structures, the reforms underway within the NHS will see a considerable movement of people and power across the new Integrated Care Systems. Wilmington Healthcare’s Victoria...
We must be candid about our use of healthcare data if we want to win back public trust
As the government announces a delay to a new GP data sharing initiative amid privacy concerns, Gareth Thomas, Managing Director of Wilmington Healthcare, explains why industry must move fast to...
Wilmington Healthcare appoints new Solutions Director
Kirsty Fryer has been promoted to the role of Solutions Director for Wilmington Healthcare
Understanding the role of provider collaboratives
Oli Hudson, Content Director at Wilmington Healthcare, takes a look at the new groups of providers that are expected to play a pivotal role in integrating care.
How does the government plan to reshape the NHS?
Oli Hudson, of Wilmington Healthcare, explores the government’s new white paper, which proposes key reforms for health and social care
Integrated NHS finances: what do they mean for High Cost Drugs?
Oli Hudson and Steve How, of Wilmington Healthcare, explore NHS England’s new system-level funding and its impact on prescribing for High Cost Drugs
Covid-19: how is it affecting prescribing patterns?
Oli Hudson, Content Director at Wilmington Healthcare, analyses prescribing data in three key disease areas